celecoxib has been researched along with Tuberculosis in 2 studies
Tuberculosis: Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Celecoxib did not increase cumulative WBA of standard TB drugs (mean cumulative WBA -0." | 6.87 | Adjunctive use of celecoxib with anti-tuberculosis drugs: evaluation in a whole-blood bactericidal activity model. ( Gurumurthy, M; Hee, KH; Lee, LS; Lin, W; Lu, Q; Naftalin, CM; Paton, NI; Seng, KY; Tan, KH; Verma, R; Yeo, BCM; Yu, B, 2018) |
| "Celecoxib did not increase cumulative WBA of standard TB drugs (mean cumulative WBA -0." | 2.87 | Adjunctive use of celecoxib with anti-tuberculosis drugs: evaluation in a whole-blood bactericidal activity model. ( Gurumurthy, M; Hee, KH; Lee, LS; Lin, W; Lu, Q; Naftalin, CM; Paton, NI; Seng, KY; Tan, KH; Verma, R; Yeo, BCM; Yu, B, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carranza, C | 1 |
| Sartillo-Mendoza, LG | 1 |
| Carreto-Binaghi, LE | 1 |
| Muñoz-Torrico, M | 1 |
| Guzmán-Beltrán, S | 1 |
| Torres, M | 1 |
| Gonzalez, Y | 1 |
| Juárez, E | 1 |
| Naftalin, CM | 1 |
| Verma, R | 1 |
| Gurumurthy, M | 1 |
| Hee, KH | 1 |
| Lu, Q | 1 |
| Yeo, BCM | 1 |
| Tan, KH | 1 |
| Lin, W | 1 |
| Yu, B | 1 |
| Seng, KY | 1 |
| Lee, LS | 1 |
| Paton, NI | 1 |
1 trial available for celecoxib and Tuberculosis
| Article | Year |
|---|---|
Adjunctive use of celecoxib with anti-tuberculosis drugs: evaluation in a whole-blood bactericidal activity model.
Topics: Adult; Antitubercular Agents; Biological Assay; Blood Bactericidal Activity; Celecoxib; Cyclooxygena | 2018 |
1 other study available for celecoxib and Tuberculosis
| Article | Year |
|---|---|
Exploring COX-2 inhibitors in tuberculosis: A whole-blood model approach for immune response and adjunt therapy evaluation.
Topics: Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Humans; Immunity; Inflammati | 2023 |